Antonis S Manolis, Antonis A Manolis, Theodora A Manolis, Apostolos Vouliotis
{"title":"Chronic Obstructive Pulmonary Disease and Cardiovascular Disorders.","authors":"Antonis S Manolis, Antonis A Manolis, Theodora A Manolis, Apostolos Vouliotis","doi":"10.2174/0115701611418539260124113737","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) remains a significant global public health challenge, plagued by substantial morbidity and mortality worldwide; it is one of the main causes of death worldwide, especially during episodes of severe exacerbation. There is a higher COPD burden noted in regions with high smoking prevalence, air pollution, and faster socioeconomic development. There is also a high number of cardiovascular (CV) comorbidities among these patients, pointing to a need for routine CV screening in such circumstances. These two diseases, COPD and CV disease (CVD), are associated via an intricate and multifactorial interplay characterized by convergent risk factors, systemic inflammation, and interlinked pathophysiological mechanisms, with atherosclerosis being a principal inflammatory process linking these two disorders, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. Importantly, despite the fact that CVD is common in COPD, it remains underdiagnosed and undertreated due to overlapping respiratory and cardiac symptomatology. The latter issue is accentuated in the case of heart failure (HF) and coronary artery disease (CAD), whereby HF atypical symptoms may mimic the clinical picture of COPD exacerbation and CAD presenting with atypical symptomatology such as dyspnea on exertion and/or fatigue, which may point to HF/COPD worsening. Thus, a structured CV assessment and management following exacerbations of COPD is needed in order to identify CAD and/or other new heart disease in these patients and guide appropriate management. These issues are discussed with relevant metaanalyses and key guidelines tabulated, and the involved interrelated mechanisms are pictorially illustrated.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701611418539260124113737","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic obstructive pulmonary disease (COPD) remains a significant global public health challenge, plagued by substantial morbidity and mortality worldwide; it is one of the main causes of death worldwide, especially during episodes of severe exacerbation. There is a higher COPD burden noted in regions with high smoking prevalence, air pollution, and faster socioeconomic development. There is also a high number of cardiovascular (CV) comorbidities among these patients, pointing to a need for routine CV screening in such circumstances. These two diseases, COPD and CV disease (CVD), are associated via an intricate and multifactorial interplay characterized by convergent risk factors, systemic inflammation, and interlinked pathophysiological mechanisms, with atherosclerosis being a principal inflammatory process linking these two disorders, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. Importantly, despite the fact that CVD is common in COPD, it remains underdiagnosed and undertreated due to overlapping respiratory and cardiac symptomatology. The latter issue is accentuated in the case of heart failure (HF) and coronary artery disease (CAD), whereby HF atypical symptoms may mimic the clinical picture of COPD exacerbation and CAD presenting with atypical symptomatology such as dyspnea on exertion and/or fatigue, which may point to HF/COPD worsening. Thus, a structured CV assessment and management following exacerbations of COPD is needed in order to identify CAD and/or other new heart disease in these patients and guide appropriate management. These issues are discussed with relevant metaanalyses and key guidelines tabulated, and the involved interrelated mechanisms are pictorially illustrated.
期刊介绍:
Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.
Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).